Values as of: 2024-09-25
ETF | Health |
Last Closing
USD 142.68Change
-2.40 (-1.65)%Market Cap
USD 7.67BVolume
1.00MAnalyst Target
N/AVerdict
Verdict
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Company Website : http://www.ishares.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. |
-1.50 (-0.97%) |
USD 42.10B |
| FHLC | Fidelity® MSCI Health Care In.. |
-0.76 (-1.04%) |
USD 3.01B |
| FXH | First Trust Health Care AlphaD.. |
-1.16 (-1.04%) |
USD 1.29B |
| XHE | SPDR® S&P Health Care Equipme.. |
-0.96 (-1.07%) |
USD 0.23B |
| IDNA | iShares Genomics Immunology an.. |
-0.31 (-1.25%) |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF |
-0.55 (-1.47%) |
USD 0.12B |
| XHS | SPDR® S&P Health Care Service.. |
-1.00 (-1.04%) |
USD 0.08B |
| HTEC | Robo Global® Healthcare Techn.. |
-0.36 (-1.25%) |
USD 0.06B |
| BBP | Virtus LifeSci Biotech Product.. |
-0.76 (-1.21%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. |
-0.45 (-1.58%) |
USD 0.01B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| IBB3:LSE | 300.12 % | 0.00 % |
N/A |
N/A | |
| HAC.A:CA | 0.00 % | 3.14 % |
N/A |
N/A | |
| HAC:CA | Global X Seasonal Rotatio.. | 0.00 % | 1.27 % |
-0.01 (0%) |
CAD 0.22B |
| IBBS:LSE | -299.94 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 5.03% | 18% | F | 42% | F | ||
| Dividend Return | 0.24% | 29% | F | 4% | F | ||
| Total Return | 5.27% | 14% | F | 34% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 15.90% | 36% | F | 49% | F | ||
| Dividend Return | 0.37% | 32% | F | 4% | F | ||
| Total Return | 16.26% | 36% | F | 43% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 43.69% | 41% | F | 67% | D+ | ||
| Dividend Return | 1.60% | 37% | F | 5% | F | ||
| Total Return | 45.29% | 45% | F | 61% | D- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 3.59% | 38% | F | 53% | F | ||
| Dividend Return | 3.83% | 50% | F | 51% | F | ||
| Total Return | 0.24% | 50% | F | 7% | C- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 20.09% | 63% | D | 76% | C+ | ||
| Risk Adjusted Return | 19.07% | 50% | F | 54% | F | ||
| Market Capitalization | 7.67B | 91% | A- | 82% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
